• CSPC Pharmaceutical entered a joint venture contract with AstraZeneca to build a next-generation biologics manufacturing facility in Shijiazhuang, China.
• CSPC will hold 51% of the venture; AstraZeneca will hold 49%.
• The venture will manufacture mutually agreed biologics drug substance for global markets; scope may expand as capacity scales and demand grows.
• Partners will jointly oversee construction, operations; combines CSPC’s AI-driven GMP manufacturing system with AstraZeneca’s global quality, supply chain expertise.
• Closing remains subject to customary conditions, including regulatory approvals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260805-12272634), on August 05, 2026, and is solely responsible for the information contained therein.